Similar Effectiveness of Boceprevir and Telaprevir Treatment Regimens for Hepatitis C Virus Infection on the Basis of a Nationwide Study of Veterans

Clinical Gastroenterology and Hepatology

Volumn 12, Issue 8, 2014, Pages 1371-1380

  Ioannou, George N ^a,b   Beste, Lauren A ^a,b   Green, Pamela K ^a  

^a VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Antiviral Therapy; APRI; AST; DAA; ESA; HCV; ICD 9; LDL; Outcome; PEG IFN; Population; SVR; VA

Indexed keywords

ASPARTATE AMINOTRANSFERASE; BOCEPREVIR; ERYTHROPOIETIN; INTERLEUKIN 28B; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; TELAPREVIR; ALBUMIN; BILIRUBIN; HEMOGLOBIN; ALPHA INTERFERON; ANTIVIRUS AGENT; N-(3-AMINO-1-(CYCLOBUTYLMETHYL)-2,3-DIOXOPROPYL)-3-(2-((((1,1-DIMETHYLETHYL)AMINO)CARBONYL)AMINO)-3,3-DIMETHYL-1-OXOBUTYL)-6,6-DIMETHYL-3-AZABICYCLO(3.1.0)HEXAN-2-CARBOXAMIDE; OLIGOPEPTIDE; PROLINE;

ADULT; ARTICLE; BLACK PERSON; COMPARATIVE EFFECTIVENESS; DIABETES MELLITUS; DRUG EFFICACY; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; MAJOR CLINICAL STUDY; MALE; RECOMMENDED DRUG DOSE; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT RESPONSE; VETERAN; VIRUS LOAD; ANTIVIRAL THERAPY; CONTROLLED STUDY; DECOMPENSATED LIVER CIRRHOSIS; LIVER CIRRHOSIS; MIDDLE AGED; AGED; ANALOGS AND DERIVATIVES; CLASSIFICATION; COMPARATIVE STUDY; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; TREATMENT OUTCOME; UNITED STATES; VIROLOGY;

ADULT; AGED; ANTIVIRAL AGENTS; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; OLIGOPEPTIDES; PROLINE; TREATMENT OUTCOME; UNITED STATES; VETERANS;

EID: 84904393872     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2013.12.011     Document Type: Article

References (16)

1. Jacobson I.M., Pawlotsky J.M., Afdhal N.H., et al. Apractical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C. JViral Hepat 2012, 19(Suppl 2):1-26.
2. Available at: (available only within the VA intranet) or Accessed June 1,2012. http://www.hsrd.research.va.gov/for_researchers/vinci.
3. Kramer J.R., Giordano T.P., Souchek J., et al. The effect of HIV coinfection on the risk of cirrhosis and hepatocellular carcinoma in U.S. veterans with hepatitis C. Am J Gastroenterol 2005, 100:56-63.
4. Ioannou G.N., Splan M.F., Weiss N.S., et al. Incidence and predictors of hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol 2007, 5:938-945.
5. Davila J.A., Henderson L., Kramer J.R., et al. Utilization of surveillance for hepatocellular carcinoma among hepatitis C virus-infected veterans in the United States. Ann Intern Med 2011, 154:85-93.
6. Ioannou G.N., Bryson C.L., Weiss N.S., et al. The prevalence of cirrhosis and hepatocellular carcinoma in patients with human immunodeficiency virus infection. Hepatology 2013, 57:249-257.
7. Kramer J.R., Davila J.A., Miller E.D., et al. The validity of viral hepatitis and chronic liver disease diagnoses in Veterans Affairs administrative databases. Aliment Pharmacol Ther 2008, 27:274-282.
8. Kramer J.R., Kanwal F., Richardson P., et al. Importance of patient, provider, and facility predictors of hepatitis C virus treatment in veterans: a national study. Am J Gastroenterol 2011, 106:483-491.
9. Beste L.A., Ioannou G.N., Larson M.S., et al. Predictors of early treatment discontinuation among patients with genotype 1 hepatitis C and implications for viral eradication. Clin Gastroenterol Hepatol 2010, 8:972-978.
10. Backus L.I., Boothroyd D.B., Phillips B.R., et al. Predictors of response of US veterans to treatment for the hepatitis C virus. Hepatology 2007, 46:37-47.
11. Kanwal F., Hoang T., Kramer J.R., et al. Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection. Gastroenterology 2011, 140:1182-1188.
12. Miller D.R., Safford M.M., Pogach L.M. Who has diabetes? Best estimates of diabetes prevalence in the Department of Veterans Affairs based on computerized patient data. Diabetes Care 2004, 27(Suppl 2):B10-B21.
13. Wai C.T., Greenson J.K., Fontana R.J., et al. Asimple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003, 38:518-526.
14. Vallet-Pichard A., Mallet V., Nalpas B., et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection-comparison with liver biopsy and fibrotest. Hepatology 2007, 46:32-36.
15. Zeuzem S., Heathcote E.J., Shiffman M.L., et al. Twelve weeks of follow-up is sufficient for the determination of sustained virologic response in patients treated with interferon alpha for chronic hepatitis C. JHepatol 2003, 39:106-111.
16. Clark P.J., Thompson A.J., Zhu M., et al. Interleukin 28B polymorphisms are the only common genetic variants associated with low-density lipoprotein cholesterol (LDL-C) in genotype-1 chronic hepatitis C and determine the association between LDL-C and treatment response. JViral Hepat 2012, 19:332-340.